Recent advances in triple negative breast cancer: the immunotherapy era

BACKGROUND: Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marra, Antonio, Viale, Giulia, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507064/
https://www.ncbi.nlm.nih.gov/pubmed/31068190
http://dx.doi.org/10.1186/s12916-019-1326-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507064/
https://www.ncbi.nlm.nih.gov/pubmed/31068190
http://dx.doi.org/10.1186/s12916-019-1326-5

Ejemplares similares